drugset / Trial / NCT00849368

Azathioprine & Allopurinol in Inflammatory Bowel Disease Patients

NCT00849368

Phase 1 Completed 6 enrolled University of Zurich
NaSingle-groupOpen-labelTreatment

Summary

Main Study Objectives: The study is conducted to * evaluate the minimal allopurinol and azathioprine doses that, in combination, produce therapeutic 6-TGN levels * evaluate the safety and tolerability of the different allopurinol/azathioprine dose levels * assess if concomitant allopurinol affects TPMT activity * assess the clinical efficacy of concomitant allopurinol-azathioprine therapy in the included patients

Timeline

Start
2009-01
Primary completion
2011-09
Completion
2011-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Allopurinol Small molecule 100 mg Oral
Subject Azathioprine Small molecule 25 mg Oral
Subject Azathioprine Small molecule 50 mg Oral